Literature DB >> 3014936

Natural mycobacteriostatic activity in human monocyte-derived adherent cells.

G S Douvas, E M Berger, J E Repine, A J Crowle.   

Abstract

The effects of human monocyte maturity on the replication of virulent Mycobacterium tuberculosis were examined. Mycobacteria grew readily in freshly isolated, adherent peripheral blood monocytes and in monocyte-derived macrophages obtained after 7 days in culture, as measured by counts of acid-fast bacilli and colony-forming units. Monocytes cultured for only 3 days before infection, however, were less permissive for the mycobacteria than either uncultured or 7-day cells. The association between the low permissiveness of 3-day cells and superoxide production was examined. Mycobacteria induced only a slight increase in superoxide production during the first 60 min of infection in uncultured and in 3-day cells, and no increase in cells cultured for 7 days before infection. Freshly isolated adherent cells produced small amounts of superoxide in response to phorbol myristate acetate (PMA) stimulation, but PMA-induced superoxide production increased steadily for 7 days. Mycobacteria had no effect on superoxide production by PMA-stimulated adherent cells. These results suggest that the suppressive activity of the 3-day cells is not associated with the production of increased amounts of reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014936     DOI: 10.1164/arrd.1986.134.1.44

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

1.  Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication.

Authors:  P K Mehta; C H King; E H White; J J Murtagh; F D Quinn
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  Immunopathology of tuberculosis: roles of macrophages and monocytes.

Authors:  M J Fenton; M W Vermeulen
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

Review 3.  Immunization against tuberculosis: what kind of vaccine?

Authors:  A J Crowle
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

4.  Human immunodeficiency virus type 1 enhances intracellular growth of Mycobacterium avium in human macrophages.

Authors:  G Källenius; T Koivula; K J Rydgård; S E Hoffner; A Valentin; B Asjö; C Ljungh; U Sharma; S B Svenson
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

5.  Expression of virulence of Mycobacterium tuberculosis within human monocytes: virulence correlates with intracellular growth and induction of tumor necrosis factor alpha but not with evasion of lymphocyte-dependent monocyte effector functions.

Authors:  R F Silver; Q Li; J J Ellner
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

6.  Monocyte antimycobacterial activity before and after Mycobacterium bovis BCG vaccination in Chingleput, India, and London, United Kingdom.

Authors:  S H Cheng; K B Walker; D B Lowrie; D A Mitchison; R Swamy; M Datta; R Prabhakar
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages.

Authors:  A J Crowle; E J Ross; M H May
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

8.  Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid.

Authors:  J Scott Ferguson; Jeremy J Weis; Jennifer L Martin; Larry S Schlesinger
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Characterization of inhibition of Mycobacterium avium replication in macrophages by normal human serum.

Authors:  G S Douvas; M H May; E Ross; A J Crowle
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

10.  Nonadherent cultures of human monocytes kill Mycobacterium smegmatis, but adherent cultures do not.

Authors:  K Barker; H Fan; C Carroll; G Kaplan; J Barker; W Hellmann; Z A Cohn
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.